Evidence map›Paper›PMID 31706638›Full record

Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2020

Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.

Sarah H Lisanby, Shawn M McClintock, George Alexopoulos, Samuel H Bailine, Elisabeth Bernhardt, Mimi C Briggs, C Munro Cullum, Zhi-De Deng, Mary Dooley, Emma T Geduldig and 19 more

Open access · greenAbstract readClinical Trial, Phase IMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022
    Trial
  4. Electroconvulsive Therapy Pulse Amplitude and Clinical Outcomes.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. The Effects of Baseline Impaired Global Cognitive Function on the Efficacy and Cognitive Effects of Electroconvulsive Therapy in Geriatric Patients: A Retrospective Cohort Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Understanding Vulnerability to Late-Life Suicide.Current psychiatry reports · 2021
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 1 country.

Sarah H LisanbyDivision of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine (SHL - Now at the National Institute of Mental Health; SMM, MMH), Durham, NC; Noninvasive Neuromodulation Unit, Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health (SHL, Z-DD), Bethesda, Maryland.
Shawn M McClintockDivision of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine (SHL - Now at the National Institute of Mental Health; SMM, MMH), Durham, NC; Department of Psychiatry, UT Southwestern Medical Center (SMM, CMC, MMH), Dallas, TX. Electronic address: shawn.mcclintock@utsouthwestern.edu.
George AlexopoulosDepartment of Psychiatry and Behavioral Sciences, New York Presbyterian/Weill Cornell Medical Center (GA, VL, RCY), White Plains, NY.
Samuel H BailineDepartment of Psychiatry, Zucker Hillside Hospital/North Shore-LIJ Health System (SHB, SK, GP), New York, NY.
Elisabeth BernhardtDepartment of Nursing, Duke University School of Medicine (EB), Durham, NC.
Mimi C BriggsDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai (MCB, ETG, LSL, CHK), New York, NY.
C Munro CullumDepartment of Psychiatry, UT Southwestern Medical Center (SMM, CMC, MMH), Dallas, TX.
Zhi-De DengNoninvasive Neuromodulation Unit, Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health (SHL, Z-DD), Bethesda, Maryland.
Mary DooleyDepartment of Public Health Sciences, College of Medicine, Medical University of South Carolina (MD, RGK, MM, AAT), Charleston, SC.
Emma T GeduldigDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai (MCB, ETG, LSL, CHK), New York, NY.
Robert M GreenbergNYU Langone (RMG), New York, NY.
Mustafa M HusainDivision of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine (SHL - Now at the National Institute of Mental Health; SMM, MMH), Durham, NC; Department of Psychiatry, UT Southwestern Medical Center (SMM, CMC, MMH), Dallas, TX.
Styliani KalioraDepartment of Psychiatry, Zucker Hillside Hospital/North Shore-LIJ Health System (SHB, SK, GP), New York, NY.
Rebecca G KnappDepartment of Public Health Sciences, College of Medicine, Medical University of South Carolina (MD, RGK, MM, AAT), Charleston, SC.
Vassilios LatoussakisDepartment of Psychiatry and Behavioral Sciences, New York Presbyterian/Weill Cornell Medical Center (GA, VL, RCY), White Plains, NY.
Lauren S LiebmanDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai (MCB, ETG, LSL, CHK), New York, NY.
William V McCallDepartment of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University (WVM, PBR), Augusta, GA.
Martina MuellerDepartment of Public Health Sciences, College of Medicine, Medical University of South Carolina (MD, RGK, MM, AAT), Charleston, SC.
Georgios PetridesDepartment of Psychiatry, Zucker Hillside Hospital/North Shore-LIJ Health System (SHB, SK, GP), New York, NY.
Joan PrudicDepartment of Psychiatry, Columbia University/New York State Psychiatric Institute (JP), New York, NY.
Peter B RosenquistDepartment of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University (WVM, PBR), Augusta, GA.
Matthew V RudorferDivision of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health (MVR), Bethesda, MD.
Shirlene SampsonDepartment of Psychiatry and Psychology, Mayo Clinic (SS), Rochester, MN.
Abeba A TeklehaimanotDepartment of Public Health Sciences, College of Medicine, Medical University of South Carolina (MD, RGK, MM, AAT), Charleston, SC.
Kristen G TobiasVA New Jersey Health Care System (KGT), East Orange, NJ.
Richard D WeinerDepartment of Psychiatry and Behavioral Sciences, Duke University (RDW), Durham, NC.
Robert C YoungDepartment of Psychiatry and Behavioral Sciences, New York Presbyterian/Weill Cornell Medical Center (GA, VL, RCY), White Plains, NY.
Charles H KellnerDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai (MCB, ETG, LSL, CHK), New York, NY.
CORE/PRIDE Work Group
Icahn School of Medicine at Mount Sinai · USMedical University of South Carolina · USNational Institute of Mental Health · USCornell University · USDuke University · USZucker Hillside Hospital · USAugusta University · USNew York Psychoanalytic Society and Institute · USSouthwestern Medical Center · USVA New Jersey Health Care System · US

Funding

Non-invasive Neuromodulation Unit (NNU)ZIAMH002955 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2016 to 2025
$40.3M
2/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH084241 · NIMH · DUKE UNIVERSITY · PI WEINER, RICHARD D. · 2009 to 2013
$2.1M
1/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH055495 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KELLNER, CHARLES H · 2009 to 2013
$2.0M
3/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH081362 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KNAPP, REBECCA GRANT · 2009 to 2013
$1.8M
7/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH086127 · NIMH · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCCALL, WILLIAM VAUGHN · 2009 to 2013
$1.1M
8/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH086122 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI YOUNG, ROBERT C. · 2009 to 2013
$1.0M
5/8-Prolonging Remission in Depressed Elderly (PRIDE)U01MH086130 · NIMH · MAYO CLINIC ROCHESTER · PI SAMPSON, SHIRLENE MARIE · 2009 to 2011
$610k
NIMH NIH HHS U01 MH055495NIMH NIH HHS U01 MH081362NIMH NIH HHS U01 MH084241NIMH NIH HHS U01 MH086122NIMH NIH HHS U01 MH086127NIMH NIH HHS U01 MH086130
6 · The paper itself

Abstract

objectiveThere is limited information regarding the tolerability of electroconvulsive therapy (ECT) combined with pharmacotherapy in elderly adults with major depressive disorder (MDD). Addressing this gap, we report acute neurocognitive outcomes from Phase 1 of the Prolonging Remission in Depressed Elderly (PRIDE) study.

methodsElderly adults (age ≥60) with MDD received an acute course of 6 times seizure threshold right unilateral ultrabrief pulse (RUL-UB) ECT. Venlafaxine was initiated during the first treatment week and continued throughout the study. A comprehensive neurocognitive battery was administered at baseline and 72 hours following the last ECT session. Statistical significance was defined as a two-sided p-value of less than 0.05.

resultsA total of 240 elderly adults were enrolled. Neurocognitive performance acutely declined post ECT on measures of psychomotor and verbal processing speed, autobiographical memory consistency, short-term verbal recall and recognition of learned words, phonemic fluency, and complex visual scanning/cognitive flexibility. The magnitude of change from baseline to end for most neurocognitive measures was modest.

conclusionThis is the first study to characterize the neurocognitive effects of combined RUL-UB ECT and venlafaxine in elderly adults with MDD and provides new evidence for the tolerability of RUL-UB ECT in an elderly sample. Of the cognitive domains assessed, only phonemic fluency, complex visual scanning, and cognitive flexibility qualitatively declined from low average to mildly impaired. While some acute changes in neurocognitive performance were statistically significant, the majority of the indices as based on the effect sizes remained relatively stable.

Indexed as

Electroconvulsive TherapyAgedCombined Modality TherapyFemaleHumansMajor Depressive DisorderMaleNeurocognitive DisordersNeuropsychological TestsTreatment OutcomeVenlafaxine HydrochlorideVenlafaxine Hydrochlorideelectroconvulsive therapygeriatricMajor depressive disordermemoryneuropsychology

Identifiers

PMID31706638
PMCPMC7050408
OpenAlexW2979612805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.